Daratumumab-Mediated lysis of primary multiple myeloma cells is enhanced in combination with the human Anti-KIR antibody IPH2102 and lenalidomide

Haematologica

Volumn 100, Issue 2, 2015, Pages 263-268

  Nijhof, Inger S ^a,b   Van Bueren, Jeroen J Lammerts ^c   Van Kessel, Berris ^a,b   Andre, Pascale ^d   Morel, Yannis ^d   Lokhorst, Henk M ^a,b   Van De Donk, Niels W C J ^b   Parren, Paul W H I ^c,e   Mutis, Tuna ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GENMAB   (Netherlands)

^d INNATE PHARMA   (France)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DARATUMUMAB; DRUG ADMINISTRATION; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; GENOMIC DNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LENALIDOMIDE; LIRILUMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; PHARMACOLOGY; THALIDOMIDE;

ANALOGS AND DERIVATIVES; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; BIOLUMINESCENCE; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER CELL CULTURE; CELL CULTURE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG POTENTIATION; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETICS; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NATURAL KILLER CELL; PATHOLOGY; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY; TREATMENT OUTCOME; WESTERN BLOTTING;

ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; FLOW CYTOMETRY; GENETICS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGY; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHARMACOLOGY; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IGG; RECEPTORS, KIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THALIDOMIDE; THERAPY;

EID: 84964255580     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.117531     Document Type: Article

References (28)

1. Howlader N, Noone AM, and Krapcho M. SEER Cancer Statistics Review, 1975-2010. Available http://seer.cancer.gov/csr/1975_2 010/. Accessed June 30, 2014.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-339.
3. Barlogie B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Crowley J. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia. 2008;22:1633-1636.
4. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-2526.
5. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149-157.
6. de Weers M, Tai YT, van der Veer M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematologi-cal tumors. J Immunol. 2011;186:1840-1848.
7. Lokhorst HM, Laubach JP, Nahi H, et al. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). J Clin Oncol. 32:5s[2014]. 8513.
8. van der Veer M, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011; 96:284-290.
9. van der Veer M, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1:e41.
10. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
11. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503-510.
12. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-469.
13. Benson DM, Jr., Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118:6387-6391.
14. Romagne F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667-2677.
15. Benson DM, Jr., Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120:4324-4333.
16. Korde N, Carlsten M, Lee MJ, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014;99:e81-e83.
17. van der Spek E, Bloem AC, Lokhorst HM, van KB, Bogers-Boer L, van de Donk NW. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res. 2009;33:100-108.
18. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109-1114.
19. Jiang XM, Arepally G, Poncz M, McKenzie SE. Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods. 1996;199:55-59.
20. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood. 1999;94:4220-4232.
21. van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003;61:189-202.
22. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
23. Lioznov M, El-Cheikh J Jr, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant. 2010;45:349-353.
24. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cyto-toxicity in multiple myeloma. Blood. 2001;98:210-216.
25. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128:192-203.
26. van de Donk NW, Görgün G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012;4:253-268.
27. Kohrt HE, Thielens A, Marabelle A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014; 123(5):678-686.
28. Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. 2012;8:1209-1222.